TÁC DỤNG KHÔNG MONG MUỐN CỦA PHÁC ĐỒ PEMETREXED – CARBOPLATIN ĐIỀU TRỊ UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ SAU KHÁNG THỨ PHÁT VỚI THUỐC ỨC CHẾ EGFR TYROSINE KINASE

Abstract

Objective: To evaluate the side -effects of the seconde – line Pemetrexed - Carboplatin regimen in advanced non-small cell lung cancer after accquired resistance to EGFR TKIs treated. Objects and methods: 46 patients with advanced non-small cell lung cancer with EGFR mutation, secondary resistance to TKIs, no or unknown T790M mutation, treatment withPemetrexed - Carboplatin. Retrospective studies. Evaluate side - effects according to CTCAE4.0 criteria. Results: Leukopenia 10.6%, Neutropenia 12.6%, Reduced hemoglobin 31.6%, Thrombocytopenia 0%. Increased liver enzymes 6%, Renal toxicity 0%, Vomiting 6.5%, Diarrhea 4.2%. Side effects of grade 3 or higher are very rare, with no death due to treatment. Conclusion: The Pemetrexed - Carboplatin regimen is well tolerated in patients with NSCLC after secondary resistance to the inhibitor Tyrosine Kinase.